Zisoo kS. Side effects of isocarboxazid. J Clin. Psych 1984; 45: 53–8.
Anthony M, Lance JW
. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969; 21: 263–8.PubMed
Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest 1952; 21: 3.
Zeller EA, Barsky J, Fouts JR, Kircheimer WF, Van Orden LS
. Influence of isonicotinic and hydrazine (INH) and l-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experentia (Basel) 1952; 8: 349–50.CrossRef
. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol 1958; 19: 72–8.PubMed
Goldberg LI. Monoamine oxidase inhibitors: adverse reactions and possible mechanisms. JAMA 1964; 190: 132–8.
Sheehan DV, Claycomb JB. The use of MAO inhibitors in clinical practice.In: Psychiatric Medicine Update, Manschreck TC, Murray GB (Eds). Massachusetts General Hospital reviews for physicians, New York, Elsevier 1984; 143–62.
Biel H. Monoamine oxidase inhibitor antidepressants. Structure activity relationships.In: Principles of Psychopharmacology, Clark WG, Del Guidice J (Eds). New York: Academic Press 1970; 269–78.
Blackwell B, Marley E, Price J, Taylor D
. Hypertensive interactions between MAO inhibitors and foodstuffs. Br J Psychiatry 1967; 113: 349–65.PubMedCrossRef
Singer TP, Van Korff RW, Murphy DL. Monoamine oxidase: structure, function and altered functions. New York: Academic Press 1979; 477–96.
Murphy DL, Garrick NA, Aulakh CS, Cohen RM. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psych 1984; 45: 37–43.
Johnston JP. Some observations upon a new monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–97.
Cantham RM, Pintar JE, Haseltine FP et al
. Differences in the structure of A and B forms of human monoamine oxidase. J Neurochem 1981; 37: 363–72.CrossRef
Brown GK, Powell JF, Craig TW
. Molecular weight differences between human platelet and placental monoamine oxidase. Biochem Pharmacol. 1980; 29: 2595–603.PubMedCrossRef
Denny RM, Fritz RR Patel NT et al
. Human liver MAO-A and MAO-B separated by immunoaffinity chromatography with MAO-B-specific monoclonal antibody. Science 1982 215: 1400–3.CrossRef
Tipton KF,Fowler CJ,Houslay MD, Specificities of the two forms of monoamine oxidase.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982; 87-99.
Suzuki O,Katsumata Y,Oya H. Substrate specificity of type A and type B monoamine oxidase.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Usdin E, Nagatsu T (Eds). 1982; 74–86.
Fowler CJ, Ross SB
. Selective inhibitors of monoamine oxidase A and B; biochemical, pharmacological and clinical properties. Med Res Reviews 1984; 4: 323–58.CrossRef
Lewinsohn R, Glover V, Sandler M
, Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 1980; 29: 1221–30.PubMedCrossRef
Glover V, Sandler M
. Clinical chemistry of monoamine oxidase. Cell Biochem. Funct 1986; 4: 89–97.PubMedCrossRef
Schnaitman C, Erwin VG, Greenawalt JW
. The submitochondrial localisation of monoamine oxidase. J Cell Biol 1967; 32: 719–35.PubMedCrossRef
. The natural history of amine oxidases. Physiol Biochem Pharmacol 1974; 70: 83–148.CrossRef
Glover V, Sandler M
. Clinical chemistry of monoamine oxidase. Cell Biochem. Funct 1986; 4: 89–97.PubMedCrossRef
Schildkrant JI. The catecholamine hypothesis of affective disorders. A review of the supporting evidence. Am J Psychiatry 1963; 122: 509–22.
Neff NH, Costa E
. The influence of monoamine oxidase inhibition on catecholamine synthesis. Life Sciences 1966; 5: 951–8.PubMedCrossRef
Lin RC, Neff NH, Nga SH et al
. Turnover rates of serotonin and norepinephrine in brain of normal and pargyline-treated rats. Life Sciences 1969; 8: 1077–84.PubMedCrossRef
Kapin IJ. False transmitters revisited: their role in the hypotensive action of MAO inhibitors.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982.
Finberg JPM. Effects of selective inhibition of MAO types A and B on peripheral sympathetic function.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982.
Aghajanian GK. Influence of drugs on the firing of serotonin-containing neurons in brain. Fed Proc Am Soc Exp Biol 1972; 31: 91–6.
Campbell IC, Murphy DL, Gallager DW et al. Neurotransmitter related adaption in the central nervous system following chronic monoamine oxidase inhibition.In: Monoamine oxidase: structure, function and altered functions. Singer TP, Von Korff RW, Murphy DL (Eds). New York, Academic Press 1979.
Cohen RM, Anlakh CS, Campbell K et al
. Functional subsensitivity of a-adrenoreceptors accompanies reductions in yohimbine binding after clorgyline treatment. Eur J Pharmacol 1982; 81: 145–8.PubMedCrossRef
Simpson GM, White K
. Tyrarnine studies and the safety of MAOI drugs. J Clin Psychiatry 1984; 45: 59–61.PubMed
Mann JJ, Aarons SF, Frances AJ, Brown RD
. Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiatry 1984; 45: 62–6.PubMed
Lader MH, Sakalis G, Tansella M
. Interaction between sympathetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 1972; 18: 118–23.CrossRef
. The present status of monoamine oxidase inhibitors. Brit J Psychiatry 1985; 146: 576–84.CrossRef
Birkmayer W, Riederer P, Yondim MBH
. (-)deprenyl in the treatment of Parkinson’s disease. Clin Neuropharmac 1982; 5: 195–230.CrossRef
Elsworth JD, Glover V, Reynolds GP et al
. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect.” Psychoparmacology 1978; 57: 33–8.CrossRef
. The possible mechanisms of action of (-)deprenyl in Parkinson’s disease. J Neural Transmission 1978; 43: 177–98.CrossRef
Richards LE, Burger A. Mechanism-based inhibitors of monoamine oxidase. Prog Drug Res 1987; 30: 205–19.
Benedetti MS, Boucher T, Carlsson A, Fowler CJ
. Intestinal metabolism of tyrarnine by both forms of monoamine oxidase in the rat. Biochem Pharmacol 1983; 32: 47–52.PubMedCrossRef
Hedley ED, Snyder SH
. Relationship between the action of monoamine oxidase inhibition on the noradrenaline uptake system and their antidepressant efficacy. Nature 1968; 220: 1330–1.CrossRef
LaRoche MJ, Brodie BB
. Lack of relationship between inhibition of monoamine oxidase and potentiation of hexobarbital hypnosis. J Pharmacol Exp Ther 1960; 130: 134–7.PubMed
Bowman WC, Rand MJ. A Textbook of Pharmacology (2nd ed). Blackwell Scientific Publications, Oxford 1980; 11. 7–11.11.
Mantle TJ, Tipton KF, Garrett NJ
Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 1976; 25: 2073–7.PubMedCrossRef
Fowler CJ, Callingham BA, Mantle TJ, Tipton KF
. The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase -A and -B. Biochemical Pharmacol 1980; 29: 1177–83.CrossRef
Yasuhara, H, Wada I, Sakamoto K. Inhibitory effects of B-blockers and local anaesthetics on monoamine oxidase and their membrane effects.In: Monoamine oxidase: basic and clinical frontiers. Kamija K, Usdin E, Nagatsu T (Eds). Excerpta Medica, Amsterdam 1982; 251–61.
. Inhibition of human brain type B monoamine oxidase by tricyclic psychoactive drugs. Mol Pharmacol 1978; 14: 164–71.PubMed
Roizen MF. Anesthetic implications of concurrent disease.In: Miller RD (Ed). Anesthesia. 2nd ed. New York: Churchill Livingstone, 1986; 331–2.
. Monoamine oxidase inhibitors. Anaesthesia 1964; 19: 376–86.PubMedCrossRef
Davidson J, Zung WW, Walker JI
. Practical aspects of MAI inhibitor therapy. J Clin Psychiatry 1984; 45 (sec. 2): 81–4.PubMed
Jenkins LC, Graves HB
. Potential hazards of psychoactive drugs in association with anaesthesia. Can Anaesth Soc J 1965; 12: 121–8.PubMedCrossRef
Brown TCK, Cass NM
. Beware - the use of MAO inhibitors is increasing again. Anaesth Intensive Care 1979; 7: 65–8.PubMed
Sheean DV, Claycomb JB, Kouretas N. Monoamine oxidase inhibitors: prescription and patient management. Int J Psych Med 1980-1981; 10(2): 99–121.
. The use of pethidine and morphine in the presence of monoamine oxidase inhibitors. Br J Anaesth 1968; 40: 279–82.PubMedCrossRef
Wong KC, Puerto AX, Puerto BA, Blatnick RA
. Influence of imipramine and pargyline on the arrythmogenicity of epinephrine during halothane, enflurane or methoxyflurane anaesthesia in dogs. Life Sciences 1980; 27: 2675–8.PubMedCrossRef
Braverman B, Ivankovich AD, McCarthy R. The effects of fentanyl and vasopressors on anaesthetized dogs receiving MAO inhibitors. Anesth Analg 1984; 63: 192 (Abs).
El-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R
. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg 1985; 64: 592–6.PubMedCrossRef
Michaels I, Serrings M, Shier N, Barash PG
. Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors. Anesth Analg 1984; 63: 1041–4.PubMed
Ayd F. Should monoamine oxidase inhibitors be discontinued preoperatively? Int. Drug Therapy Newsletter 1986; 21(6): 24.
Wong KC. Preoperative discontinuation of monoamine oxidase inhibitor therapy: an old wives tale? Sem Anes 1986; 5: 145–8.
. Hypertension during anaesthesia with monoamine oxidase inhibitors. Anaesthesia 1987; 42: 633–5.PubMedCrossRef
. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Int Med 1955; 42: 417–24.PubMed
Papp C, Benaim S
. Toxic effects of iproniazid in a patient with angina. Br Med J 1958; 2: 1070–2.PubMed
. Dangerous potentiation of pethidine by iproniazid and its treatment. Br Med J 1960; 2: 507–9.PubMed
Palmer H. Potentiation of pethidine. Br Med J 1960; 2: 944.
. Alarming reaction to pethidine in patients on phenelzine. Lancet 1962; 2: 401–2.CrossRef
Denton PH, Borell VM, Edwards NV. Dangers of monoamine oxidase inhibitors. Br Med J 1962; 2:1752.
Spencer GT, Smith SE
. Dangers of monoamine oxidase inhibitors. Br Med J 1963; 1: 750.PubMed
. Anaesthesia and monoamineoxidase inhibitors. Br Med J 1965; 1: 520.PubMed
Rogers KJ, Thornton JA
. The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br J Pharmacol 1969; 36: 470–80.PubMed
Dostert P. Myth and reality of the classical MAO inhibitors. Reasons for seeking a new generation.In: Tipton KF, Dostert P, Benedetti MS (Eds). Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press, 1984: 9–25.
. Anaesthesia and MAO inhibitors. Br Med J 1965; 1: 1126.PubMed
Penn RG, Rogers KJ
. Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with an MAO. Br J Pharmacol 1971; 42: 485.PubMed
Brown DD, Waldron DH
. An unusual reaction to tranylcypromine. Practitioner 1962; 189: 83–5.PubMed
Baldessarini RJ. Drugs and the treatment of psychiatric disorders.In: Gillman AC, Goodman LS, Gilman A (Eds). The pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980: 427–30.
Youssef MS, Wilkinson PA
. Epidural fentanyl and monoamine oxidase inhibitors. Anaesthesia 1988; 43: 210–2.PubMedCrossRef
Hirsch MS, Walter RM, Hasterlik RJ
. Subarachnoid hemorrhage following ephedrine and MAO inhibitor. JAMA 1965; 194: 1259.PubMedCrossRef
Cousins MJ, Maltby JR
. Delayed recovery of sympathetic transmission following ten years MAO inhibition. Br J Anaesth 1971; 43: 803–6.PubMedCrossRef
Hirsch MS, Walter RM, Hauterlik RJ
. Subarachnoid hemorrhage following ephedrine and MAO inhibitors. JAMA 1965; 194: 1259.PubMedCrossRef
Horler AR, Wayne NA
. Hypertensive crises due to pargyline and metaraminol. Br Med J 1965; 2: 460–1.PubMed
Mason A. Fatal reaction associated with tranylcypromine and methylamphetamine. Lancet 1962; 1: 173–7.
Cuthbert MF, Greenberg MP, Morley SW
. Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J 1969; 1: 404–6.PubMed
. Hypertensive crisis due to MAO inhibitors. Lancet 1963; 2: 849–51.PubMedCrossRef
Elis J, Laurence Dr, Manie H, Prichard BNC
. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on the blood pressure. Br Med J 1967; 2: 75–8.PubMed
Hunter KR, Boakes AJ, Laurence Dr, Sterne GM. Monoamine oxidase inhibitors and L-dopa. Br Med J 1970; 3: 338.
Horwitz D, Goldberg LI, Sjoerdsma A
. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitor in man. J Lab Clin Med 1960; 56: 747–53.PubMed
Janowsky EC, Risen SC, Janowsky DS. Psychotropic agents.In: Smith TY, Miller RD, Corbascio AN (Eds). Drug Interactions in Anesthesia. Philadelphia: Lea and Febinger, 1981: 177–95.
. A review of the danger of monoamine oxidase inhibitors, with special reference to anesthesia. S Afr Med J 1965; 39: 10–4.PubMed
Boakes AJ, Teoh PC, Barar FKS, Benedikter LT, Prichard BNC. Interaction between sympathomimetic amines and antidepressant agents in man. B Med J 1973; 1: 311–5.
Wulfsohn NL, Politzer WM
. 5-Hydroxytryptamine in anaesthesia. Anaesthesia 1962; 17: 64–8.PubMedCrossRef
Fouts JR,Brodie BB. On the mechanism of drug potentiation by iproniazid. J Pharmacol Exp Ther 1956; 116–480–5.
Gaines GY, Ress DI
. Electroconvulsive therapy and anesthetic considerations. Anesth Analg 1986; 65: 1345–56.PubMedCrossRef
Domino EF, Sullivan TS, Buby ED. Barbiturate intoxication in a patient treated with a MAO inhibitor. Am J Psych 1962; 118:941–3.
Bodley PO, Halwax K, Potts L
. Low serum pseudocholinesterase levels complicating treatment with phenelzine. Br Med J 1969; 3: 510–2.PubMedCrossRef
Sjoquist F. Psychotropic. (2) Interaction between monoamine oxidase (MAOI) inhibitors and other substances. Proc R Soc Med 1965; 58: 967.
Johnston RR, Eger EI, Wildon C
. A comparative interaction of epinephrine with enflurane, isoflurane and halothane in man. Anesth Analg 1976; 55: 709–12.PubMedCrossRef